WHO-GMP sourced EU-GMP partners ISO 9001:2015 49+ export markets Since 2003

Pharmaceutical Exporter from India to Brazil.

Brazilian registration depends on ANVISA, which issues Good Manufacturing Practices certificates (CBPF) for each production line, including for manufacturing sites in other countries, and that shapes everything we do for Brazilian buyers. M Care Exports is an Indian pharmaceutical exporter with Mumbai operations, London and Dubai commercial desks, and a dossier discipline tuned to the way ANVISA reads a CTD. We supply Brazilian importers and private hospital networks with WHO-GMP oncology, biosimilars, anti-infectives, and surgical consumables, routing volume primarily through Santos with Guarulhos for time-critical cold-chain. The Portuguese-language documentation investment is built into our process, not bolted on.

WHO-GMP sourcing CDSCO licensed exporter EU-GMP capable partners ISO 9001:2015 SGS GDP Certified Pharmexcil RCMC FIEO Member Cold-chain validated CTD / eCTD ready
Regulatory environment

ANVISA, Portuguese CTD, and the inspection regime that defines Brazilian pharmaceutical import

ANVISA, Agência Nacional de Vigilância Sanitária, is the federal regulator that gates pharmaceutical product registration, manufacturing-site recognition, and importation in Brazil. ANVISA decides on Good Manufacturing Practices certification itself, using its own inspection reports or the inspection information of regulators it recognises as equivalent, and issues a Certificado de Boas Práticas de Fabricação (CBPF) for each production line of a site. A registration filing for a synthetic or semi-synthetic medicine must include a valid CBPF for the production line concerned, or a copy of the inspection request protocol.

For synthetic and semi-synthetic medicines, official documents in a foreign language used for registration need a sworn translation, except those presented in English or Spanish, so translation has to be planned document by document. Translation quality, terminology consistency with Brazilian Pharmacopoeia conventions, and alignment of stability data with the conditions ANVISA applies for Brazil's climatic zone IVb all need attention. We work with Portuguese pharmaceutical translation specialists rather than generic translators, and we prepare the quality documentation for each filing against the ANVISA rules that apply to that product.

On the commercial side, a company that imports medicines into Brazil must hold an Autorização de Funcionamento de Empresa (AFE) from ANVISA. Public-sector buying is split between the Ministério da Saúde, which buys some programme medicines centrally, and state and municipal health authorities, which buy others; private hospitals and hospital groups buy separately from the public system. Each channel buys differently, and we adapt the export pack accordingly.

Brazil has its own pharmaceutical manufacturers, including public laboratories, and for several biological medicines the Ministério da Saúde has run productive development partnerships with them, rituximab and trastuzumab with Bio-Manguinhos/Fiocruz among them. We focus our Brazil practice on biosimilars, niche oncology molecules and anti-infectives, and check each molecule against local availability before we quote.

Call & WhatsApp the Mumbai desk: +91 70156 05768 · [email protected] · Mon–Sat 09:30–18:30 IST

What we do for Brazilian customers

Capabilities calibrated to ANVISA documentation and Santos-route freight

ANVISA-aware dossier authoring

CTD modules drafted with ANVISA reviewer expectations in mind, including zone IVb stability framing, Portuguese terminology consistency, and cross-referencing of the foreign-site inspection certificate.

Portuguese pharmaceutical translation

Full Module 1, 2, and 3 translation through specialists familiar with Brazilian Pharmacopoeia language, not general translators. Labelling, IFU, and patient information leaflet localisation included.

Biosimilar and oncology supply

Cold-chain validated supply of biosimilar oncology and supportive-care molecules, checked molecule by molecule against Brazilian availability. Mumbai-to-Guarulhos lane for time-critical biological consignments.

SUS and private-channel separation

Distinct documentation packs and pricing logic for federal SUS procurement, state Secretarias de Saúde tenders, and private hospital network buying desks.

Foreign-site inspection support

Coordination with our Indian manufacturing partners ahead of ANVISA on-site audits, including pre-audit gap reviews and documentation staging in the format inspectors will request.

Santos and Guarulhos lane planning

Sea consolidation through Mumbai-Nhava Sheva to Santos for ambient pharma; air freight Mumbai-Guarulhos for cold-chain biologicals with validated insulated packaging.

Mumbai to Santos and Guarulhos

Freight from Mumbai to São Paulo, Santos, and Rio with cold-chain integrity

The main sea lane we plan for Brazil runs from Mumbai (Nhava Sheva) to Santos. Sea transit time depends on the carrier's routing and any transhipment, so we confirm the sailing schedule with the carrier at booking rather than quoting a fixed number of days. We consolidate ambient-stable oral solids and parenterals on this lane, with documentation staged in Portuguese ahead of vessel arrival so the importer's despachante can begin clearance the moment the bill of lading hits.

For temperature-sensitive consignments, biosimilars, oncology biologicals, vaccines requiring 2 to 8°C, we route by air through Mumbai to Guarulhos (GRU). Active temperature-controlled containers and validated passive shippers are matched to consignment value and lane duration. Where the end customer base sits in Rio state, we can route to Galeão (GIG) Rio instead. Itajaí and Paranaguá can be considered as alternative sea ports, depending on the importer's location and the carrier's schedule.

Pre-shipment, we run the documentation pack through ANVISA-format Portuguese review before the container loads. Post-arrival, we coordinate with the Brazilian importer on AFE-licensed warehousing, lot release, and chain-of-custody for SUS or private hospital onward delivery. The freight side is engineered, not improvised.

Formulary focus

Where Indian supply matches Brazilian demand

Brazil has its own domestic pharmaceutical manufacturers, and we do not pretend to displace them. We look at biosimilar oncology and supportive-care molecules that a Brazilian buyer may need to import, and we check each molecule against local availability first, because the Ministério da Saúde has run productive development partnerships with public laboratories for biologicals such as rituximab and trastuzumab.

Anti-infectives are a second focus. The Ministério da Saúde buys medicines for tuberculosis, antiretrovirals and viral hepatitis treatment centrally, so for those programmes we work from the ministry's tender specifications. Cardiovascular and CNS generics are supplied through private-hospital channels on commercial terms.

Cold-chain biologicals and specialty injectables form the third pillar. Vaccines for private clinic use, immunoglobulins, and selected biologicals move through our validated cold-chain. We do not push commodity categories where local manufacturing already meets demand.

A São Paulo private-hospital network had been sourcing biosimilar oncology through a European consolidator with sea freight arriving via Antwerp transhipment, adding two weeks to lead time and a 1.4°C excursion event in the prior calendar year. They approached us in late 2025 looking for direct Mumbai-to-Santos cold-chain on three biosimilar molecules used across their oncology day-care units. We staged the Portuguese CTD update through our translation desk in three weeks, coordinated with the Indian manufacturer to refresh stability data in zone IVb format, and ran the first consolidated container Mumbai to Santos in just under 33 days. Cold-chain integrity held across the lane, lot release through the importer's AFE-licensed warehouse cleared within four working days, and onward distribution to the network's three flagship hospitals completed within a week of port arrival. The procurement head described the documentation discipline as the differentiator. The freight was the visible part; the dossier rhythm was what made the relationship workable.

Illustrative operational case Brazil · Private hospital network procurement · Biosimilar oncology
Why M Care for Brazil

An Indian pharmaceutical exporter that respects how ANVISA reads a dossier

Brazil is a market where the regulatory bar is high and the consequences of treating documentation casually are expensive. ANVISA grants its own Good Manufacturing Practices certificate for each production line, based on its inspection reports or those of regulators it recognises as equivalent. For synthetic and semi-synthetic medicines, official documents in a foreign language need a sworn translation unless they are in English or Spanish. Stability data has to follow the conditions ANVISA sets for Brazil's climatic zone IVb. We have built our Brazil practice around those realities rather than against them. The Portuguese translation pipeline, the foreign-site inspection coordination, the SUS-versus-private channel separation, these are not value-adds, they are the table stakes for being a serious Indian pharmaceutical supplier to Brazil.

The therapeutic focus matters as much as the process discipline. We focus on biosimilar oncology, supportive-care molecules, anti-infectives for federal programmes, and cold-chain specialty injectables, and we check each molecule against local availability before we quote. That positioning, combined with the Mumbai-to-Santos lane discipline and Guarulhos cold-chain capability, is what we offer Brazilian importers and hospital networks who want a pharmaceutical exporter to Brazil that thinks like an ANVISA reviewer and ships like a logistics specialist.

Brazil FAQ

Common questions from Brazilian importers and hospital procurement

Does M Care hold ANVISA foreign-site inspection certification on its supply manufacturers?

ANVISA grants its Certificado de Boas Práticas de Fabricação for each establishment by production line, so a certificate for one line does not cover another. We match each enquiry to a manufacturer whose relevant production line already holds a valid certificate, and we confirm that status for the specific molecule before quoting. Where a Brazilian buyer wants a molecule from a site that does not yet hold the certificate, we coordinate the certification process with the manufacturer, but we are upfront that the timeline is set by ANVISA and this is not a quick fix. We do not misrepresent inspection status.

Which Brazilian ports and airports does M Care typically route through?

Sea freight is planned mainly through Santos, the default consolidation point for our ambient and refrigerated container traffic into Brazil. Itajaí and Paranaguá can be considered as alternative sea ports, depending on the importer's location and the carrier's schedule. For cold-chain and time-critical consignments, air freight runs Mumbai to Guarulhos (GRU) São Paulo as the primary lane, with Galeão (GIG) Rio used where the end-customer base is Rio-state-centric. We confirm the routing with the importer at order acceptance based on consignment temperature profile and onward distribution geography.

Is the CTD dossier always required in Portuguese?

Not always. For synthetic and semi-synthetic medicines, RDC 753/2022 requires official documents in a foreign language used for registration to carry a sworn translation, except those presented in English or Spanish. We confirm document by document which items need translation, and for biological products we check the applicable rule at enquiry stage. We work with Brazilian Pharmacopoeia-aware pharmaceutical translators rather than general-purpose translators because terminology consistency matters to reviewer experience.

How does SUS public procurement differ from private hospital network buying?

The Ministério da Saúde finances and buys centrally the medicines of its strategic pharmaceutical assistance component, which covers tuberculosis and other endemic diseases, antiretrovirals and viral hepatitis treatment. Many other medicines are bought by municipal and state health authorities. Private hospitals and hospital groups buy separately, on commercial terms. We maintain distinct documentation packs and commercial templates for each channel.

Is M Care US-FDA registered, and does that matter for Brazil?

We are not US-FDA registered, and for the Brazilian market it does not affect our ability to supply. ANVISA issues its own Certificado de Boas Práticas de Fabricação, based on its own inspection reports or those of regulators it recognises as equivalent, so the certificate that matters for registration is ANVISA's. Our Indian manufacturing partners hold WHO-GMP certification and, where relevant for the product line, ANVISA Certificado de Boas Práticas de Fabricação.

What invoicing currency and payment terms apply to Brazil shipments?

International commercial invoicing is in USD as standard, with the Brazilian importer handling BRL conversion at their banking counterparty. Standard terms are letter of credit at sight or documents-against-payment for first transactions, moving to open account on negotiated terms once a relationship is established.

Can M Care support biosimilar oncology supply specifically?

Yes, biosimilars are one of our core focus categories for Brazil. Because several biological medicines have been the subject of public-laboratory partnerships in Brazil, we check local availability for each molecule first. We supply biosimilar finished forms with cold-chain validated freight from Mumbai through Guarulhos, paired with ANVISA-format Portuguese dossiers, foreign-site inspection certification, and stability data structured to zone IVb requirements. Biosimilar work demands tighter documentation and freight discipline than commodity generics, and we have built our Brazil practice around exactly this.

Indian pharmaceutical supply built for Brazil

Mumbai to São Paulo, with the dossier discipline Brazil rewards

ANVISA dossier discipline

Portuguese CTD authored to ANVISA reviewer conventions, zone IVb stability framing, and foreign-site inspection coordination built into the supply relationship from day one.

Santos and Guarulhos lanes

Mumbai-to-Santos sea consolidation for ambient pharma and Mumbai-to-Guarulhos air freight for cold-chain biologicals, with onward coordination through AFE-licensed Brazilian warehousing.

Biosimilar oncology focus

Therapeutic positioning aimed at biosimilars, niche oncology and anti-infectives, rather than commodity orals.

Shop by therapeutic area

Top categories we ship to Brazil

Talk to us about Brazil

Send the molecule list, the channel, and the timeline

If you are sourcing for SUS tender consolidation, a private hospital network, or a Brazilian importer building an Indian-origin portfolio, send us the molecule list with intended channel and target landed timing. We come back with manufacturer match, ANVISA dossier status, lane recommendation between Santos and Guarulhos, and an indicative timeline that respects the foreign-site inspection reality. No generic pitch deck.

Start a Brazil enquiry → Back to all markets

Buying for repeat supply? Open a trade account for a named account manager and priced quotes.